Results 21 to 30 of about 12,992 (201)

Aplicaciones terapéuticas del eculizumab [PDF]

, 2022
Introducción: El eculizumab es un anticuerpo monoclonal de tipo IgG diseñado para el tratamiento de la hemoglobinuria paroxística nocturna (HPN), en el que su diana farmacológica forma parte del sistema del complemento.
Campos González, Natalia, Chacón-Jiménez, Luz, Ruiz Jiménez, Susana, Rodríguez-Jiménez, Johanna, Chacón Jiménez, Luz María, Ruiz-Jiménez, Susana, Rodríguez Jiménez, Johanna, Campos-González, Natalia   +7 more
core   +1 more source

Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series

Brain Sciences, 2021
(1) Background: Complement system activation has been proposed as one of the different factors that contribute to Multiple Sclerosis (MS) pathogenesis. In this study, we aimed to describe the potential effects of eculizumab, an anticomplement therapy, on
Marco Allinovi, Angelo Bellinvia, Francesco Pesce, Sabrina Milan Manani, Lorenzo Razzolini, Brigida Brezzi, Paolo Protopapa, Vittorio Mantero, Leonardo Caroti, Calogero Lino Cirami, Maria Pia Amato, Lucia Del Vecchio   +11 more
doaj   +1 more source

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria [PDF]

, 2021
Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease characterized by chronic complement-mediated hemolysis. C5 inhibition controls intravascular hemolysis in untreated PNH but cannot address extravascular hemolysis ...
Panse, Jens Peter, Peffault de la Tour, Régis, Höchsmann, Britta, Szer, Jeff, Ilene Weitz, Panse, Jens, Röth, Alexander, Jeff Szer, Weitz, Ilene, Régis Peffault de la Tour, de la Tour, Régis Peffault, Tan, Lisa, Carlos de Castro, Deschatelets, Pascal, Kensuke Usuki, Griffin, Morag, Hillmen, Peter, Hisakazu Nishimori, Jens Panse, Britta Höchsmann, Temitayo Ajayi, Mohamed Hamdani, de Castro, Carlos, Antonio Risitano, Kiladjian, Jean-Jacques, Hamdani, Mohamed, Usuki, Kensuke, Risitano, Antonio, Jean-Jacques Kiladjian, Lisa Tan, Alexander Röth, Nishimori, Hisakazu, Cedric Francois, Ajayi, Temitayo, Grossi, Federico, Peter Hillmen, Morag Griffin, Francois, Cedric, Pascal Deschatelets, Federico Grossi   +39 more
core   +2 more sources

Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort

PLoS ONE, 2021
Background Atypical Hemolytic Uremic Syndrome (aHUS) is an ultra-rare disease that potentially leads to kidney graft failure due to ongoing Thrombotic Microangiopathy (TMA).
Hong Si Nga, Lilian Monteiro Pereira Palma, Miguel Ernandes Neto, Ida Maria Maximina Fernandes-Charpiot, Valter Duro Garcia, Roger Kist, Silvana Maria Carvalho Miranda, Pedro Augusto Macedo de Souza, Gerson Marques Pereira, Luis Gustavo Modelli de Andrade   +9 more
doaj   +2 more sources

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder

Frontiers in Neurology, 2021
Objective: To investigate the pharmacokinetics and pharmacodynamics of the approved 900/1,200 mg dosing regimen for the terminal complement component 5 (C5) inhibitor eculizumab in patients with neuromyelitis optica spectrum disorder (NMOSD).Methods ...
Pratap Singh, Xiang Gao, Huub Jan Kleijn, Francesco Bellanti, Ryan Pelto   +4 more
doaj   +1 more source

Placental disposition of eculizumab, C5 and C5‐eculizumab in two pregnancies of a woman with paroxysmal nocturnal haemoglobinuria [PDF]

, 2021
Contains fulltext : 232079.pdf (Publisher’s version ) (Open Access)Eculizumab is known to cross the placenta to a limited degree, but recently therapeutic drug levels in cord blood were found in a single case.
Petra H.H. van den Broek, Joris van Drongelen, Olivier W.H. van der Heijden, Broek, P.H.H. van den, Russel, F.G.M., Rick Greupink, Sarlea, A., Heijden, O.W.H. van der, Eliesen, G.A.M., Drongelen, J. van, Volokhina, E.B., Andrei Sarlea, Elena B. Volokhina, Frans G.M. Russel, Gaby A.M. Eliesen, Langemeijer, S.M., Saskia Langemeijer, Greupink, R.   +17 more
core   +1 more source

Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.

PLoS ONE, 2020
IntroductionEculizumab is a licensed treatment for several rare, complement-mediated diseases. Eculizumab use is associated with an approximately 2,000-fold increased meningococcal disease risk.
Catherine H Bozio, Cheryl Isenhour, Lucy A McNamara   +2 more
doaj   +1 more source

Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan

Therapeutic Advances in Neurological Disorders, 2023
Background: The terminal complement C5 inhibitor eculizumab is approved in Japan for relapse prevention in aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) and is undergoing mandatory post-marketing surveillance (PMS ...
Ichiro Nakashima, Jin Nakahara, Hiroaki Yokote, Yasuhiro Manabe, Kazumi Okamura, Kou Hasegawa, Kazuo Fujihara   +6 more
doaj   +1 more source

Eculizumab hepatotoxicity in pediatric aHUS. [PDF]

, 2015
BACKGROUND Eculizumab is a humanized anti-C5 antibody approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Its use is increasing in children following reports of its safety and efficacy.
Hayes, Wesley, Tschumi, Sibylle, Feber, Janusz, Ling, Simon C, Licht, Christoph, Kirschfink, Michael   +5 more
core   +2 more sources

Cumulative survival (days) in the Brazilian aHUS cohort patients divided by groups: Not received eculizumab (red), prophylactic eculizumab (green), and eculizumab treatment (blue).

, 2021
Cumulative survival (days) in the Brazilian aHUS cohort patients divided by groups: Not received eculizumab (red), prophylactic eculizumab (green), and eculizumab treatment (blue).
Hong Si Nga (4592092), Valter Duro Garcia (5221406), Lilian Monteiro Pereira Palma (4592095), Luis Gustavo Modelli de Andrade (4592089), Roger Kist (7528070), Pedro Augusto Macedo de Souza (11663289), Ida Maria Maximina Fernandes-Charpiot (7586720), Miguel Ernandes Neto (11663283), Silvana Maria Carvalho Miranda (11663286), Gerson Marques Pereira Jr (11663292)   +9 more
core   +1 more source